EXHIBIT B3

November 2026 Medical Drug Recommendations to EBD Commissions						
No.	**Drug**	**Treating Diagnosis**	**Current**	**Recommendation**	**Cost (AWP)**	**Impacted members**
1	Hepcludex (bluevirtide acetate-GMOD 8.5mg vials)	Chronic Hepatitis D	NTM	**Exclude**	$339,976 per year	0
2	Decnupaz (pivekimab sunirine-PVZY 2mg vial)	Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults	NTM	**Exclude**	$221,581 per 21 days, continue until disease progression or toxicity	0
3	Nufymco (ranibizumab-LEYK 0.3mg or 0.5mg/0.05mL)	Wet AMD, macular edema due to diabetes, macular retinal edema, myopic choroidal neovasularization, retinopathy due to diabetes	NTM	**No EBRx Restrictions**	$9,000-$19,000 per year	0
4	Yesafili (aflibercept-JBVF 2mg/0.05mL)		NTM	**No EBRx Restrictions**	$12,000 – 14,000 per year based on diagnosis	0
5	Vabysmo (faricimab)		No EBRx Restrictions	**Exclude**	$18,000 - $27,000 per year	212 (lifetime grandfather)
6	Tregzi (allo reg Tcell, HSPC, Tcell-VLDQ)	Post stem cell transplant	NTM	**Exclude**	$428,000 post stem cell transplant	0
7	Lumvoa (velicrotug-vvze 500mg/10mL vial)	Thyroid eye disease	NTM	**EBRx PA**	$313,600	0
8	Tepezza (teprotumumab)		No EBRx Restrictions	**Exclude**	$408,000	0
9	Lutathera (lutetium Lu 177 dotatate)	Gastroenteropancreatic neuroendocrine tumors	Exclude	**EBRx PA**	$140,000 per 4 dose course	3 (positive change)
10	Pluvicto (IV lutetium Lu 177 vipivotide tetraxetan)	Prostate cancer	Exclude	**EBRx PA**	$306,000 per 6 dose course	1 (positive change
11	Revtorpyk (gedatolisib 180mg vial)	Breast cancer	NTM	**EBRx PA**	$36,000 per 28 days	0
12	Kisunla (donanemab)	Mild Alzheimer disease	Exclude	**EBRx PA**	$4.185 per 2mg	0

NTM = new to market, PA = Prior Authorization, OS = Overall Survival, ORR = Overall Response Rate, MCID = Minimally Important Clinical Difference, No EBRx Restrictions = coverage will fall under Health Advantage policy

PA will be managed by EBRx, If no change occurs then the drug was re-reviewed by EBRx clinical committee for new data but no change in coverage